Previously the Live Forever Club — same community, now with a sharper mission for life extension

Bart Keymeulen

Professor of medicine at Vrije Universiteit Brussel and diabetologist at UZ Brussel, specialising in type 1 diabetes and beta cell replacement

Bart Keymeulen is a full professor in the Faculty of Medicine and Pharmacy at Vrije Universiteit Brussel (VUB) and a diabetologist at UZ Brussel, where he leads integrated, multidisciplinary care for all forms of diabetes with a particular focus on type 1 diabetes. He chairs the VUB research cluster on Diabetes, Transplantation and Pathology and is honorary president of the Belgian Diabetes League.

His research aims to bring new therapies to people at every stage of type 1 diabetes, from prevention before diagnosis to treatment later in the disease. This includes immunotherapy to suppress the autoimmune attack on insulin-producing cells and the transplantation of beta cells, or stem cell-derived cells that mature into beta cells. He has been a principal investigator in clinical trials of stem cell-derived islet replacement therapy, and in 2022 he received the Hilde Bruers Prize for scientific research in medicine.

Visit website: https://www.uzbrussel.be/fr/web/diabeteskliniek/diabetologues/-/asset_publisher/yR1bwnadaSIc/content/prof-dr-bart-keymeulen

See also

Vrije Universiteit Brussel (VUB)

Internationally oriented university in Brussels

Details last updated 16-Nov-2026

Bart Keymeulen News

ViaCyte stem cell implant shows first signs of insulin production in diabetes

ViaCyte stem cell implant shows first signs of insulin production in diabetes

Endpoints News - 25-Jun-2021

Stem cell therapy triggers insulin production in a type 1 diabetes patient

DoNotAge supplements affiliate link